Dr Kaustav Talapatra named ASTRO’s International Ambassador from India

Jacobio Pharma partners with AstraZeneca in $2 billion licensing deal for pan-KRAS inhibitor

Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China

Niagen Bioscience secures full ownership of key NAD+ patents in major IP move

The portfolio includes foundational patents on the production, composition, and commercial use of NR

Bayer wins Japan nod for finerenone in broad heart failure population

Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients

China approves first-in-class TGCT drug, marking global first for pimicotinib

FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy

The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity

TAKE Solutions plans AI-driven healthcare platform

The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities

Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder

The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1

Novo Nordisk files FDA application for once-weekly obesity drug CagriSema

If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection

GenSci, RTW & Yarrow Bioscience strike $1.365 billion global deal for breakthrough graves’ disease therapy

GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies